Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
Argenx Se (ARGX) Stock Price & Analysis
434 Followers
ARGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$327.73 - $539.79
Previous Close$471.32
Volume54.51K
Average Volume (3M)312.23K
Market Cap
$27.64B
Enterprise Value$25.88B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Jul 25, 2024EPS Estimate
-$0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.17
Shares Outstanding59,194,488
10 Day Avg. Volume268,232
30 Day Avg. Volume312,228
Standard Deviation0.12
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.88
Price to Sales (P/S)19.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue121.43
Enterprise Value/Gross Profit23.35
Enterprise Value/Ebitda-56.76
Forecast
1Y Price Target
$512.78Price Target Upside9.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Argenx Se News
Bulls Say, Bears Say
Bulls Say
Clinical Data And TrialsNew details from the Phase 2 RHO trial of efgart in Sjogren’s disease showed encouraging clinical improvements vs. placebo across a range of disease composite scores.
Market ExpansionManagement revised its Total Addressable Market for MG to approximately 60k patients, indicating a much larger opportunity than previously thought.
Regulatory ApprovalsVyvgart sc won the NMRA approval to become the first and only sc FcRn blocker for gMG patients in China.
Bears Say
Clinical DataDescartes-08's Ph.2b gMG topline data doesn't look competitive vs Vyvgart.
Insurance And PricingHigher price could potentially make the insurance process much more difficult.
Market ChallengesShares have largely traded sideways, indicating limited movement in the stock despite recent developments.
---
Ownership Overview
0.00%
Insiders
25.90% Mutual Funds
2.00% Other Institutional Investors
72.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $327.73 and its highest was $539.78 in the past 12 months.
What is Argenx Se’s market cap?
Currently, no data Available
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Jul 25, 2024 which is in 3 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on May 09, 2024. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.771 by -$0.269.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is -$0.9.
How many shares outstanding does Argenx Se have?
Argenx Se has 59,796,272 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.771. Following the earnings report the stock price went down -0.914%.
Which hedge fund is a major shareholder of Argenx Se?
Among the largest hedge funds holding Argenx Se’s share is Baker Bros Advisors LP. It holds Argenx Se’s shares valued at 60M.
---
Argenx Se Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$512.78 (9.88% Upside)
$512.78 (9.88% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 78.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.81%
12-Months-Change
Fundamentals
Return on Equity
-8.55%
Trailing 12-Months
Asset Growth
44.93%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
ARGX Company Deck
---
ARGX Earnings Call
Q1 2024
0:00 / 0:00
---
ARGX Stock 12 Month Forecast
Average Price Target
$512.78
▲(9.88% Upside)
Technical Analysis
Best Analysts Covering ARGX
1 Year
1 Year Success Rate
20/22 ratings generated profit
1 Year Average Return
+37.60%
reiterated a buy rating 6 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +37.60% per trade.
---